Abstract
Abstract: Peripheral artery disease (PAD) is a prevalent cardiovascular disease with risks of limb loss. Our objective is to establish an autologous cell source for vascular regeneration to achieve limb salvage in PAD. Six PAD patients (age 50–80) were enrolled with their peripheral blood collected to derive vascular endothelial cells (ECs) with two different approaches: (1) endothelial progenitor cell (EPC) approach and (2) induced pluripotent stem cell (iPSC) approach. The iPSC approach successfully generated patient-specific ECs for all PAD patients, while the EPC approach did not yield any colony-forming ECs in any of the patients. The patient-derived iPSC-ECs expressed endothelial markers and exhibited endothelial functions. However, elevated inflammatory status with VCAM-1 expression was observed in the patient-derived cells. Pharmacological treatment with resveratrol resulted in patient-specific responses in cell viability and VCAM-1 expression. Our study demonstrates the potential of iPSC-ECs for autologous regenerative therapy in PAD, offering promise for personalized treatments for ischemic PAD. Graphical Abstract: (Figure presented.) Our study establishes autologous endothelial cells from induced pluripotent stem cells as a cellular resource for regenerative treatments in peripheral artery disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 558-569 |
| Number of pages | 12 |
| Journal | Journal of Cardiovascular Translational Research |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2024 |
Funding
We thank Dr. Melina Kibbe and Dr. Karen Ho from Northwestern Memorial Hospital (Chicago, IL) for clinical support throughout the project. We also thank members from the Clinical Research Units of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute for coordination and nursing services. This work was supported by the equipment, training, and services from the Northwestern University RHLCCC Flow Cytometry Facility (Evanston and Chicago, IL) and the Stem Cell Core Facility (Chicago, IL). This work is funded by the National Institute of Health (5R01EB017129), the American Heart Association (14POST20160091 and 19TPA34890008), and the Chicago Biomedical Consortium (PDR-008).
Keywords
- Endothelial cells
- Induced pluripotent stem cells
- Peripheral artery disease
- Regenerative medicine
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmaceutical Science
- Cardiology and Cardiovascular Medicine
- Genetics(clinical)
